Skip to main content

Table 1 Patient characteristics

From: FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study

Factor

N (%)

Age (years)

 median (range)

67 (48–84)

Sex

 Male

30 (69.8)

 Female

13 (30.2)

ECOG PSa

 0

11 (25.6)

 1–2

32 (74.4)

Disease status

 Metastatic

34 (79.1)

 Recurrence

9 (20.9)

Treatment line

 Third line

34 (79.1)

 Fourth line

5 (11.6)

 Fifth line

4 (9.3)

CEAb (ng/mL)

 median (range)

11.6 (2.5–669.7)

CA 19–9c (U/mL)

 median (range)

2762.7 (0–115,360.2)

CRPd (mg/dL)

 median (range)

1.46 (0.03–10.0)

Haemoglobin (g/dL)

 median (range)

11.4 (13.9–8.1)

Albumin (g/dL)

 median (range)

3.5 (2.2–4.2)

Germline BRCA mutation

 Positive

1 (2.3)

 Negative

30 (76.7)

 Not assessed

9 (20.9)

Reason for discontinuation of 5-FU/LV + nal-IRIe

 Progression

42 (97.7)

 Intolerable toxicity

1 (2.3)

  1. a ECOG PS Eastern Cooperative Oncology Group performance status
  2. b CEA Carcinoembryonic antigen
  3. c CA 19–9 Carbohydrate antigen 19–9
  4. d CRP C-reactive protein
  5. e 5-FU/LV + nal-IRI Fluorouracil, leucovorin, and nanoliposomal-irinotecan combination therapy